- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT02012582
Phase 2 a Study to Assess Safety and Pharmacokinetics of VAS203 in Patients With Traumatic Brain Injury (NOSTRA)
An Exploratory Phase 2 a Study to Assess Safety, Tolerability, Pharmacodynamic and Pharmacokinetics of VAS203 in Patients With Moderate and Severe Traumatic Brain Injury
In the exploratory multi-center Phase 2 a study safety, tolerability, pharmacodynamics and pharmacokinetics of the Nitric Oxide Synthase inhibitor VAS203 is assessed in patients with moderate and severe traumatic brain injury. Traumatic brain injury patients (32 males) receive 15, 20 and 30 mg/kg VAS203, respectively, by continuous infusion in three cohorts (Cohort 1 open; Cohorts 2 and 3 double blind, randomised placebo-controlled). End of Study for all patients will be Day 14; adverse events and concomitant medications will be documented throughout the study.
Objectives are to assess safety and tolerability of VAS203, to evaluate concentrations of metabolites of VAS203 in plasma and microdialysate and to assess pharmacodynamic effects of VAS203 on surrogate parameters. Safety parameter will include vital signs (blood pressure heart rate, respiration rate, oxygen saturation and blood gases), fluid balance, ECG, laboratory examinations (clinical chemistry, liver function, haematology/coagulation, urinalysis, renal parameters) and adverse events. Concentration of VAS203 will be determined in plasma and microdialysate. Pharmacodynamic parameters will include intracranial pressure (ICP), biochemical parameters in microdialysate (nitrite/nitrate, arginine, citrulline, pyruvate, lactate, glucose), Partial Oxygen Pressure in brain parenchyma and Therapy Intensity Level (TIL).
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
Intravenous administration of study medication for each patient will start as soon as possible but not later than 12 hours after trauma. Patients in Group 1 will receive open label study drug (VAS203). Patients in Group 2 and 3 will be randomised to treatment with VAS203 or placebo.
In addition to study treatment, each patient will receive the best "standard of care" for the study centre; no treatment will be withheld.
Studientyp
Einschreibung (Tatsächlich)
Phase
- Phase 2
Kontakte und Standorte
Studienorte
-
-
-
Toulon, Frankreich, 83800
- HIA Sainte-Anne Boulevard Sainte-Anne
-
-
-
-
-
Zuerich, Schweiz, 8091
- University Hospital Zuerich Surgical Intensive Care
-
-
-
-
-
Barcelona, Spanien, 08035
- Vall d'Hebron University Hospital Department of Neurosurgery
-
Barcelona, Spanien, 08036
- Hospital Clinic University of Barcelona Surgical Intensive Care Unit
-
-
-
-
-
Southampton, Vereinigtes Königreich, SO16 6YD
- Southampton University Hospital Division of Clinical Neurosciences
-
-
-
-
-
Innsbruck, Österreich, 6020
- Medical University Innsbruck Department of Neurology
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Written informed consent from patient's legal guardian or legal representative
- 18 - 65 years of age, inclusive
- Head trauma within the last 12 hours
- Traumatic brain injury with Glasgow Coma Score (GCS) ≥ 5 and that requires ICP monitoring
- Catheter placement for monitoring and management of increased ICP
- Microdialysis probe placement in penumbra zone or ipsilateral to contusion if focal
- Systolic blood pressure ≥ 100 mmHg
- Females of child-bearing potential must have a negative pregnancy test
Exclusion Criteria:
- Penetrating head injury (e.g. missile, stab wound)
- Not expected to survive more than 24 hours after admission
- Concurrent, but not pre-existing, spinal cord injury
- Unilateral and bilateral fixed and dilated pupil (> 4 mm)
- Cardiopulmonary resuscitation performed post injury
- continuing bleeding likely to require multiple transfusions (> 4 units red blood cells)
- Coma due to a "pure" epidural hematoma (lucid interval and absence of structural brain damage on CT scan)
- Coma suspected to be primarily due to other causes than head injury (e.g. drug overdose)
- Known or CT scan evidence of pre-existing major cerebral damage
- Decompressive craniectomy, planned prior to randomization
- Polytraumatic patients with Injury Severity Score > 25, or rhabdomyolysis
- Injuries to ascending aorta and/or carotid arteries
- serum creatinine values > 1.5 mg/dL
- estimated Glomerular Filtration Rate < 60 ml/min (MDRD-formula)
- body mass index (BMI) > 35, Body weight > 120 kg
- Any severe concomitant condition (cancer; hematologic, renal, hepatic, coronary disease; major psychiatric disorder; alcohol or drug abuse), that can be ascertained at admission
- Known to have received an experimental drug within 4 weeks prior to current injury
- Administration of > 100 ml of contrast media containing iodine
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Vervierfachen
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
---|---|
Experimental: VAS203 15 mg/kg
Three 5 mg/kg/12-hours infusion with 12 hours break after each infusion.
Total dose: 15 mg/kg
|
i.v. infusion
Andere Namen:
|
Experimental: VAS203 20 mg/kg
10 mg/kg/24 hours, 48 hour continuous infusion.
Total dose: 20 mg/kg
|
i.v. infusion
Andere Namen:
|
Experimental: VAS203 30 mg/kg
10 mg/kg/24 hours, 72 hour continuous infusion.
Total dose: 30 mg/kg
|
i.v. infusion
Andere Namen:
|
Placebo-Komparator: Saline
0.9 % Sodium chloride infusion
|
i.v. infusion
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Safety and Tolerability of VAS203 in Patients With Moderate and Severe TBI
Zeitfenster: 14 days
|
Tolerability (good, satisfactory, sufficient, poor) of VAS203 in patients with moderate and severe TBI, as judged by the investigators at day 14. Safety outcome measure description see safety section |
14 days
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Duration (Number of Time-points) of Intracranial Pressure (ICP) > 20 mmHg
Zeitfenster: Hourly from start of infusion to 144 hours
|
Hourly from start of infusion to 144 hours
|
|
Duration (Number of Hours) of Cerebral Perfusion Pressure (CPP) < 60 mmHg
Zeitfenster: Hourly from start of infusion to 144 hours
|
Duration (number of hours) of cerebral perfusion pressure (CPP) < 60 mmHg calculated from ICP and mean arterial blood pressure (MAP): CPP = MAP - ICP)
|
Hourly from start of infusion to 144 hours
|
Therapy Intensity Level Score
Zeitfenster: Daily from day 1 to day 6
|
Therapy Intensity Level Score: Total Score calculated daily as the sum of all individual measures, range from 3 (good outcome) to 50 (worst outcome): Scores: 0-2 Head elevation 0-8 Sedation 0-1 Paralysis 1-3 Hyperventilation 0-2 Increased Oxygenation 1-3 Cooling 0-2 Osmotherapy 0-3 CSF Drainage 0-1 Red Blood Cell Transfusion 1-3 Cerebral perfusion pressure 0-1 Surgery for mass lesion 0/5/10 none/unilateral/bilateral Decompressive Craniectomy 0/10 Laparatomy to treat intracranial hypertension due to abdominal hypertension |
Daily from day 1 to day 6
|
Mitarbeiter und Ermittler
Sponsor
Ermittler
- Studienleiter: Frank Tegtmeier, Dr., Vasopharm GmbH
Publikationen und hilfreiche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Schätzen)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- VAS203/II/1/03
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Schädel-Hirn-Trauma
-
Kessler FoundationInstituto Vocacional Enrique Díaz de León A.C., Guadalajara, MexicoRekrutierungTBI (Traumatic Brain Injury) oder MS (Multiple Sklerose)Vereinigte Staaten, Spanien
-
National Institute of Mental Health (NIMH)AbgeschlossenBrain-MappingVereinigte Staaten
-
National Institute on Alcohol Abuse and Alcoholism...AbgeschlossenBrain-MappingVereinigte Staaten
-
Assistance Publique Hopitaux De MarseilleUnbekanntBrain Awake-ChirurgieFrankreich
-
University of Dublin, Trinity CollegeUnbekanntBrain Health Elite-Athleten im Ruhestand
-
National Institute of Mental Health (NIMH)RekrutierungGesunder Freiwilliger | Brain-MappingVereinigte Staaten
-
National Institute of Neurological Disorders and...RekrutierungGesund | Magnetresonanztomographie | Gesunder Freiwilliger | Erwachsene | fMRT | Brain-MappingVereinigte Staaten
-
Hospital Universitari Son DuretaEspen; This research prize was funded by Nestle Nutrition Institute and by Fresenius...AbgeschlossenMittelschweres bis schweres Trauma, wie durch eine definiert | In die Studie wurde ein Injury Severity Score (ISS) > 12 Punkte einbezogen.Spanien
-
National Institute of Neurological Disorders and...AbgeschlossenGesund | Blindheit | Brain-MappingVereinigte Staaten
-
National Institute of Mental Health (NIMH)AbgeschlossenfMRT | Gehirnerkrankung | Brain-Mapping | Genotyp | Allelic Frequencies of Genetic MarkersVereinigte Staaten
Klinische Studien zur VAS203
-
Vasopharm GmbHICON plcAbgeschlossenSchädel-Hirn-TraumaVereinigtes Königreich, Spanien, Frankreich, Österreich, Deutschland
-
Vasopharm GmbHWinicker Norimed GmbHAbgeschlossenBeeinträchtigung der Nierenfunktion bei gesunden FreiwilligenDeutschland